| Literature DB >> 21994631 |
Brian Hjelle1, Fernando Torres-Pérez.
Abstract
The continued emergence and re-emergence of pathogens represent an ongoing, sometimes major, threat to populations. Hantaviruses (family Bunyaviridae) and their associated human diseases were considered to be confined to Eurasia, but the occurrence of an outbreak in 1993-94 in the southwestern United States led to a great increase in their study among virologists worldwide. Well over 40 hantaviral genotypes have been described, the large majority since 1993, and nearly half of them pathogenic for humans. Hantaviruses cause persistent infections in their reservoir hosts, and in the Americas, human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary syndrome (HCPS), with case-fatality ratios, for the most common viral serotypes, between 30% and 40%. Habitat disturbance and larger-scale ecological disturbances, perhaps including climate change, are among the factors that may have increased the human caseload of HCPS between 1993 and the present. We consider here the features that influence the structure of host population dynamics that may lead to viral outbreaks, as well as the macromolecular determinants of hantaviruses that have been regarded as having potential contribution to pathogenicity.Entities:
Keywords: emergence; epidemiology; hantavirus; hantavirus cardiopulmonary syndrome; pathology
Year: 2010 PMID: 21994631 PMCID: PMC3185593 DOI: 10.3390/v2122559
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Major human-pathogenic hantaviruses.
| Virus strain | Acronym | Geographic Distribution | Host | Pathology | Case-fatality ratio (%) | |
|---|---|---|---|---|---|---|
| New World | Sin Nombre | SNV | North America | HCPS | −35 | |
| Choclo | CHOV | Panamá | HCPS | ∼21 | ||
| Andes | ANDV | Argentina, Chile | HCPS | 35 | ||
| Laguna Negra | LANV | Argentina, Bolivia, Paraguay, | HCPS | 5–15 | ||
| Old World | Hantaan | HTNV | China, Korea, Russia | HFRS | 5–0 | |
| Seoul | SEOV | Worldwide | HFRS | 1–2 | ||
| Puumala | PUUV | Scandinavia, western Europe, Russia | HFRS/NE | 0.1–0.4 | ||
| Dobrava-Belgrade | DOBV | Balkans | HFRS | 5–10 |
HCPS: Hantavirus cardiopulmonary syndrome; HFRS: Hemorrhagic fever with renal syndrome; NE: Nephropathia epidemica
Figure 1Map of hantavirus genotypes in the Americas reported to be non-pathogenic or of unknown pathogenicity (blue) and pathogenic (red) for humans. Hantaviruses reported in Soricomorpha (shrews and moles) are underlined.
Similarities and differences between HFRS and HCPS.
| HFRS | HCPS | |
|---|---|---|
| Transmission | Aerosolized wild-rodent excreta, no arthropod vector | Aerosolized wild-rodent excreta, no arthropod vector |
| Stages | Incubation period: 1–5 wk, prodrome 5–10 d, hypotensive phase 1–3 d oliguric phage 3–5 d convalescence | Incubation period: 1–5 wk, prodrome (febrile phase) 3–10 d, cardiorespiratoryphase 1–6 d diuretic phase 1–3 d convalescence |
| Primary organ of attack | Kidney, lymphoreticular system | Lungs, lymphoreticular system |
| Location of effusion | Retroperitoneal space | Thoracic bed; pulmonary interstitium |
| Pathologic hallmarks | Capillary leak. Mononuclear infiltrate. | Capillary leak. Interstitial mononuclear cell infiltrate. |
| Clinical findings | Fever, chills, nausea and vomiting, headache, lethargy, oliguria, tachycardia, facial and truncal flushing, hemorrhage, occasionally noncardiogenic pulmonary edema with tachypnea, shortness of breath, shock, death in 0.1 to 5%. | Fever, chills, nausea and vomiting, headache, lethargy, dyspnea, tachycardia, tachypnea, shortness of breath, noncardiogenic pulmonary edema, hemorrhage/petechiae (ANDV), shock, death in 10 to 50%. |
| Laboratory findings | Hypoalbuminemia, azotemia, proteinuria, hematuria, leukopenia/leukocytosis | Hypoxia, Hypoalbuminemia, thrombocytopenia, leukopenia/leukocytosis, hemoconcentration |
| Treatment | Specific: ribavirin. Nonspecific: cardioventilatory support, dialysis | Specific: none. Nonspecific: extracorporeal membrane oxygenation (ECMO), cardioventilatory support |